Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve clinical responses to improve the lives of patients with cancer. Co. is developing a number of tumor-selective, agents through various stages of development. Co.'s product candidates are XTX101, an anti-cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody and XTX202, an interleukin 2 therapy. Co. is also developing its tumor-selective IL-12 product candidate, XTX301 and is focusing on preclinical studies for its tumor-selective IL-15 product candidate, XTX401. Co. has worldwide development and commercialization rights to all of its product candidates. The XLO YTD return is shown above.
The YTD Return on the XLO YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether XLO YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the XLO YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|